IOM urges international action to eradicate fake drugs

IOM urges international action to eradicate fake drugs
Falsified and substandard medications pose public health problems around the world, and international action should be taken to combat the phenomenon, according to a report published Feb. 13 by the Institute of Medicine.

(HealthDay)—Falsified and substandard medications pose public health problems around the world, and international action should be taken to combat the phenomenon, according to a report published Feb. 13 by the Institute of Medicine (IOM).

Noting that considerable working capital is required to assure the manufacture of quality medicines, Lawrence O. Gostin, J.D., from the Georgetown University Law Center in Washington, D.C., and colleagues from the IOM reviewed the global implications of falsified medicines and recommended measures to eradicate the problem.

According to the authors, to improve the quality of medicine and protect consumers, the distribution system should be strengthened. Restriction of the U.S. wholesale market to firms approved by the National Association of Boards of Pharmacy would tighten the American drug distribution chain and encourage better control of drug wholesalers. In low- and middle-income countries, the governments should establish an appealing environment to encourage reputable private drug sellers. Falsified and substandard medicines often are ineffective, promote , and may cause illness and death, and consequently represent a serious public health concern. Eradicating these drugs will require national regulation and international cooperation. A voluntary international agreement could go some way to achieving this aim.

"Stakeholders around the world share a common interest in combating inferior-quality drugs. At the international level, productive discussion relies on cooperation and mutual trust," the authors write. "The report advocates for an emerging consensus on once-contentious terms and lays out a plan to invest in quality to improve public health."

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Supercomputers link proteins to drug side effects

Oct 20, 2014

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments